The European Medicines Agency concluded on Wednesday that AstraZeneca's COVID-19 vaccine is linked to blood clots in very rare instances. "Unusual blood clots with low blood platelets should be listed as very rare side effects," the committee said. Several countries previously paused or restricted their usage of the AstraZeneca vaccine after a few cases of blood clots were reported, largely among younger people. The EMA determined the benefits of the vaccine still outweigh its risks. "This vaccine has proven to be highly effective to prevent severe disease and hospitalization," said the committee's executive director, "and it is saving lives." U.K. regulators said Wednesday that they would recommend that people under 30 receive other vaccines. The AstraZeneca vaccine is not yet approved for use in the U.S.
need to know now